Cost and survival analysis of metastatic cerebral tumors treated by restriction and radiation. Comment.
The surgical treatment of metastatic brain tumors remains controversial, primarily because of the limited prognosis of patients with metastatic cancer.
The cost effectiveness of even standard therapic is of increasing concern to third-party payers.
We reviewed the records of patients who had a single metastatic brain tumor resected at the Medical Center Hospital of Vermont (a referral center in a rural state) since cost data recording began.
The 32 patients ranged in age from 35 to 77 years, with a 2.2:1 female-to-male ratio.
Thirty-four percent of tumors originated in the lung, 15.6% were renal, 12.5% were breast, 12.5% were gynecological, 9.4% were gastrointestinal, and 9.4% were ultimately of unknown origin.
Mots-clés Pascal : Métastase, Intracrânien, Résection chirurgicale, Traitement, Radiothérapie, Coût, Survie, Homme, Etats Unis, Amérique du Nord, Amérique, Tumeur maligne, Système nerveux pathologie, Encéphale pathologie, Système nerveux central pathologie, Chirurgie
Mots-clés Pascal anglais : Metastasis, Intracranial, Surgical resection, Treatment, Radiotherapy, Costs, Survival, Human, United States, North America, America, Malignant tumor, Nervous system diseases, Cerebral disorder, Central nervous system disease, Surgery
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0422399
Code Inist : 002B17E. Création : 199406.